Scorpion Venom Tuberculosis Drug Research Yields Alarming New Findings
Researchers at Stanford University and in Mexico have discovered that the venom of a scorpion native to Eastern Mexico contains two previously unknown compounds with powerful antimicrobial properties, including the ability to kill drug resistant tuberculosis bacteria. The team not only isolated these compounds but synthesized them in the laboratory and verified that the lab made versions were lethal to staphylococcus and multi-drug-resistant tuberculosis bacteria in both tissue samples and mice. The findings were published in the Proceedings of the National Academy of Sciences. According to the Mayo Clinic, drug resistant tuberculosis is one of the most serious public health challenges in infectious disease, making new treatment approaches urgently needed.
Why Scorpion Venom Is One of the Most Valuable Substances on Earth
The scorpion venom tuberculosis drug research draws on one of the rarest biological materials available to scientists. As study senior author Richard Zare of Stanford noted, by volume, scorpion venom is one of the most precious materials in the world, with a gallon costing an estimated $39 million to produce. This scarcity makes the ability to synthesize active compounds from venom in the laboratory not just useful but essential to any real world drug development program.
The scorpion at the center of this research, Diplocentrus melici, is native to Eastern Mexico and was collected by the group of Lourival Possani, professor of molecular medicine at the National University of Mexico. Collection itself is challenging because the scorpion remains buried during winter and dry seasons and can only be found during the rainy season. Possani has spent 45 years identifying compounds with pharmacological potential in scorpion venom and has previously uncovered antibiotics, insecticides, and anti-malarial agents within various species.
How the Scorpion Venom Tuberculosis Drug Compounds Were Discovered
When Possani’s group milked the venom of Diplocentrus melici using mild electrical pulses to stimulate the tail, they observed something unusual: the venom changed color from clear to brownish when exposed to air. Investigation revealed two chemical compounds responsible for the color change. One turned red when exposed to air, and the other turned blue.
Possani shared a sample with Zare’s group at Stanford, where postdoctoral researchers Shibdas Banerjee and Gnanamani Elumalai worked out the molecular structure of both compounds using only 0.5 microliters of venom, an amount ten times smaller than what a mosquito takes in a single feeding. Analysis confirmed that both were previously unknown benzoquinones, a class of ring-like molecules known to have antimicrobial properties. The two compounds were nearly structurally identical, with the key difference being that the red one contains an oxygen atom on one branch while the blue one contains a sulfur atom.
3 Key Findings From the Scorpion Venom Tuberculosis Drug Research
1. The Red Compound Kills Staphylococcus Bacteria
The synthesized red benzoquinone was found to be particularly effective at killing staphylococcus bacteria, a highly infectious pathogen responsible for a range of serious human infections. This finding positions the scorpion venom tuberculosis drug research as relevant not only to tuberculosis treatment but potentially to a broader class of bacterial infections.
2. The Blue Compound Kills Both Normal and Drug Resistant Tuberculosis Bacteria
The blue benzoquinone was lethal to both standard and multi-drug-resistant strains of tuberculosis causing bacteria. This is especially significant given that drug resistant tuberculosis strains have limited treatment options and represent one of the most dangerous infectious disease challenges globally. The scorpion venom tuberculosis drug compound addresses precisely the bacterial strains that existing antibiotics struggle to reach.
3. The Blue Compound Does Not Damage Lung Tissue in Mice
A critical question in any antimicrobial research is whether the compound that kills bacteria will also harm the host. Testing by Rogelio Hernandez Pando’s group at the Salvador Zubiran National Institute of Health Sciences and Nutrition in Mexico City confirmed that the blue compound kills tuberculosis bacteria while leaving the lining of the lungs in mice intact. This selective toxicity is essential for any viable scorpion venom tuberculosis drug candidate.
What Comes Next for Scorpion Venom Drug Development
Stanford and Mexican scientists are planning further collaborations to determine whether the isolated compounds can be developed into actual drugs and to investigate why these compounds are present in the venom in the first place. As Zare acknowledged, the compounds may not even be the toxic component of the venom, and the reasons the scorpion produces them remain unknown.
The synthesis breakthrough is what makes further development possible. As Possani noted, the amounts of venom components that can be obtained from live animals are extremely low, and the ability to synthesize the compounds in the laboratory was decisive for the success of this work.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active infectious disease studies, visit our patient active studies page.